<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282163</url>
  </required_header>
  <id_info>
    <org_study_id>BR1-140</org_study_id>
    <nct_id>NCT02282163</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography</brief_title>
  <official_title>A Multicenter Clinical Evaluation of Safety and Efficacy of Lumason as a Contrast Agent in Pediatric Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV
      EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the
      study in pediatric subjects represented those utilized in routine clinical practice in
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase III, multicenter, open-label study that was to be conducted at approximately
      7-12 sites in the United States, Canada and Europe in pediatric patients with suboptimal LV
      EBD on non-contrast 2D transthoracic echocardiography. It was estimated that 92 patients were
      to be enrolled to provide 73 evaluable patients.

      Three cardiologists unaffiliated with enrolling centers (blinded readers), blinded to the
      patient's identity and clinical profile were to independently evaluate the echocardiograms.
      The efficacy analysis was primarily based on the blinded reader evaluations.

      Imaging modalities that are used throughout the study in pediatric subjects represented those
      utilized in routine clinical practice in adults.

      One of the sites participating in this study was to be asked to consent a subset of patients
      for additional blood sampling for analysis of SF6 concentration in blood from a total of 6
      patients (3 males and 3 females) in the age group 9 up to 12 years of age and 6 patients (3
      males and 3 females) in the age of &gt;12 up to and including 17 years.

      The current study was designed to assess the efficacy of Lumason-enhanced echocardiography in
      pediatric patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA agreed to early termination due to difficulties enrolling patients.
  </why_stopped>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Left Ventricular Endocardial Border Delineation (LV EBD) Scores</measure>
    <time_frame>Immediately post dose-Day 1</time_frame>
    <description>The total LV EBD score for a subject was the total of the EBD scores (Inadequate - 0, sufficient - 1, Good - 2) from the 17 segments (from the apical 4-chamber, apical 2-chamber and apical long (3-chamber) views, according to the guidelines of the American Society of Echocardiography). The total LV EBD scores could range from 0 to 34 and are presented below for each of the three readers for both unenhanced ultrasound (UEUS) and contrast-enhanced ultrasound (CEUS).
Change from baseline is the difference between UEUS and CEUS in total LV EBD scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adequate Left Ventricular Opacification (LVO)</measure>
    <time_frame>Immediately post dose-Day 1</time_frame>
    <description>LVO was graded as 0 to +3, 4-point rating scale. Left ventricular opacification rating of +2 (non-homogeneous) or +3 (complete and homogeneous) was considered as adequate LVO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To obtain safety data in pediatric subjects administered Lumason for LV EBD improvement during echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Lumason</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulphur hexafluoride lipid-type A microspheres</intervention_name>
    <description>Ultrasound imaging contrast agent</description>
    <arm_group_label>Lumason</arm_group_label>
    <other_name>Lumason</other_name>
    <other_name>SonoVue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide Written informed consent from parent(s) or legal guardian

          -  Provide assent when required according to local regulations

          -  Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy for
             congenital heart disease

          -  Undergone a previous transthoracic echocardiogram within one month prior to enrollment
             resulting in suboptimal left ventricular endocardial border defined as â‰¥ 2 contiguous
             segments in any given view that cannot be visualized.

        Exclusion Criteria:

          -  Children &lt; 9 years of age

          -  Previously enrolled in the study

          -  Administered any other contrast agent either intravascularly or orally within 48 hours
             of Lumason administration

          -  Known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitated
             saline study performed before administration of Lumason)

          -  Known hypersensitivity to one or more of the ingredients of the investigational
             product

          -  Received an investigational compound within 30 days before enrolling into this study

          -  Pregnant or lactating female

          -  Determined by investigator to be unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melda Dolan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine in Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <results_first_submitted>June 1, 2020</results_first_submitted>
  <results_first_submitted_qc>June 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2020</results_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02282163/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Initiation Date (first subject enrolled): 20 October 2015; Study Completion Date (last subject completed study related activities): 20 January 2018. Enrolment was at 2 sites in the US.
Even though last subject enrolled was 20 January 2018, FDA release from completion of enrolment was 31 May 2018. Blinded read completion was 13 August 2018.</recruitment_details>
      <pre_assignment_details>The study was terminated early due to challenges with enrollment. At the time of termination, 13 subjects were enrolled and 12 subjects were dosed with Lumason, thus the efficacy analysis was considered as exploratory and p-values are not included in the Results section.
PK assessment was not performed due to enrollment difficulties.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lumason</title>
          <description>All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lumason</title>
          <description>All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.8" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age group</title>
              <category_list>
                <category>
                  <title>6 to 9 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 to 11 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12 to 15 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16-17</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.1" spread="28.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.76" spread="23.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.35" spread="12.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Left Ventricular Endocardial Border Delineation (LV EBD) Scores</title>
        <description>The total LV EBD score for a subject was the total of the EBD scores (Inadequate - 0, sufficient - 1, Good - 2) from the 17 segments (from the apical 4-chamber, apical 2-chamber and apical long (3-chamber) views, according to the guidelines of the American Society of Echocardiography). The total LV EBD scores could range from 0 to 34 and are presented below for each of the three readers for both unenhanced ultrasound (UEUS) and contrast-enhanced ultrasound (CEUS).
Change from baseline is the difference between UEUS and CEUS in total LV EBD scores.</description>
        <time_frame>Immediately post dose-Day 1</time_frame>
        <population>All subjects who received IP and had data available for both unenhanced ultrasound (UEUS) and contrast-enhanced ultrasound (CEUS) were included in ITD population.</population>
        <group_list>
          <group group_id="O1">
            <title>Off-site Reader 1 UEUS</title>
            <description>Off-site Reader 1 UEUS Assessment</description>
          </group>
          <group group_id="O2">
            <title>Off-site Reader 1 CEUS</title>
            <description>Off-site Reader 1 CEUS Assessment</description>
          </group>
          <group group_id="O3">
            <title>Off-site Reader 2 UEUS</title>
            <description>Off-site Reader 2 UEUS Assessment</description>
          </group>
          <group group_id="O4">
            <title>Off-site Reader 2 CEUS</title>
            <description>Off-site Reader 2 CEUS Assessment</description>
          </group>
          <group group_id="O5">
            <title>Off-site Reader 3 UEUS</title>
            <description>Off-site Reader 3 UEUS Assessment</description>
          </group>
          <group group_id="O6">
            <title>Off-site Reader 3 CEUS</title>
            <description>Off-site Reader 3 CEUS Assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Left Ventricular Endocardial Border Delineation (LV EBD) Scores</title>
          <description>The total LV EBD score for a subject was the total of the EBD scores (Inadequate - 0, sufficient - 1, Good - 2) from the 17 segments (from the apical 4-chamber, apical 2-chamber and apical long (3-chamber) views, according to the guidelines of the American Society of Echocardiography). The total LV EBD scores could range from 0 to 34 and are presented below for each of the three readers for both unenhanced ultrasound (UEUS) and contrast-enhanced ultrasound (CEUS).
Change from baseline is the difference between UEUS and CEUS in total LV EBD scores.</description>
          <population>All subjects who received IP and had data available for both unenhanced ultrasound (UEUS) and contrast-enhanced ultrasound (CEUS) were included in ITD population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="2.9" upper_limit="10.0"/>
                    <measurement group_id="O2" value="33.5" lower_limit="32.6" upper_limit="34.3"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.8" upper_limit="14.4"/>
                    <measurement group_id="O4" value="33.3" lower_limit="31.8" upper_limit="34.9"/>
                    <measurement group_id="O5" value="7.3" lower_limit="4.0" upper_limit="10.5"/>
                    <measurement group_id="O6" value="33.0" lower_limit="31.8" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adequate Left Ventricular Opacification (LVO)</title>
        <description>LVO was graded as 0 to +3, 4-point rating scale. Left ventricular opacification rating of +2 (non-homogeneous) or +3 (complete and homogeneous) was considered as adequate LVO.</description>
        <time_frame>Immediately post dose-Day 1</time_frame>
        <population>All subjects who received IP and had data available for contrast-enhanced ultrasound (CEUS) were included in ITD population.</population>
        <group_list>
          <group group_id="O1">
            <title>Off-site Reader 1 CEUS</title>
            <description>Off-site Reader 1 CEUS</description>
          </group>
          <group group_id="O2">
            <title>Off-site Reader 2 CEUS</title>
            <description>Off-site Reader 2 CEUS</description>
          </group>
          <group group_id="O3">
            <title>Off-site Reader 3 CEUS</title>
            <description>Off-site Reader 3 CEUS</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adequate Left Ventricular Opacification (LVO)</title>
          <description>LVO was graded as 0 to +3, 4-point rating scale. Left ventricular opacification rating of +2 (non-homogeneous) or +3 (complete and homogeneous) was considered as adequate LVO.</description>
          <population>All subjects who received IP and had data available for contrast-enhanced ultrasound (CEUS) were included in ITD population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="73.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="73.5" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="73.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>To obtain safety data in pediatric subjects administered Lumason for LV EBD improvement during echocardiography</description>
        <time_frame>Up to 72 hours post dose</time_frame>
        <population>Summary of adverse events in the safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Lumason</title>
            <description>All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>To obtain safety data in pediatric subjects administered Lumason for LV EBD improvement during echocardiography</description>
          <population>Summary of adverse events in the safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Subjects With at Least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects With AEs by Intensity - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects With AEs by Intensity -Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects With AEs by Intensity -Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were monitored for any untoward medical events from the time of signed Informed Consent through 72 hours after IP administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lumason</title>
          <description>All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behavior</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melda S. Dolan, MD, FACC, FASE, Head, Medical Affairs and Cardiac Ultrasound Programs</name_or_title>
      <organization>Bracco Diagnostics Inc.</organization>
      <phone>1-609-514-2506</phone>
      <email>Melda.Dolan@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

